24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825

Depression: Depression & Related Conditions
Resources
Basic Information
Introduction and Types of Depressive DisordersRelated Disorders / ConditionsHistorical and Current UnderstandingsBiology, Psychology and SociologyTreatment - Medication and PsychotherapyAlternative Medicine and Self-Help ResourcesSpecial IssuesReferences
More InformationTestsLatest News
Estrogen May Influence Women's Depression RiskLosing Medicaid Tough on People Battling Depression: StudyLink for Maternal Antidepressant, Kids' Brain Health QuestionedAddition of Aripiprazole Ups Major Depressive Disorder RemissionNo Sign That Antidepressants in Pregnancy Harm Kids' Brains: StudyMed Switch Not Always Best Choice With Tough DepressionDepression Contributes to Health Decline Seen in Cancer CaregiversDepression May Worsen Health for Cancer CaregiversElectric Brain Stimulation No Better Than Meds For Depression: StudyDepression Inversely Linked to Body Composition in TeensReview: Depression Screening As Inpatient Important, FeasibleDepression Can Slow Hospital Patients' Recovery: StudyAntidepressants During Pregnancy Safe for Baby: StudyChronic Pain Common in Adults With Depression, AnxietyWhat You Need to Know About AntidepressantsAPA: Internet-Based CBT Can Be Helpful in DepressionCan Online Treatment Replace Your Therapist?Depression Often a Precursor to Falls in Elderly PeopleOverweight in Childhood May Up Lifetime Risk of DepressionHeavy Kids Face Triple the Odds for Depression in AdulthoodObesity, Sex Predict Remission for Antidepressant MedicationsGender Differences in Depression Tend to Appear About Age 12Depression's Gender Gap Shows Up in Pre-Teen YearsStudies Question Link Between Mom's Antidepressant Use, Autism in KidsMortality Up With Depression Just Before Breast Cancer DiagnosisDepressive Disorders Up With Antimuscarinics for OABTrauma as a Teen May Boost Depression Risk Around MenopauseBlood Test Promising for ID of Early Depression, SchizophreniaBlood Test Might Someday Distinguish Early Depression, SchizophreniaHold That Pose: Yoga May Ease Tough DepressionDepression May Hasten Death in Years After Heart DiagnosisAntidepressant Efficacy Varies for Depressive Symptom ClustersDepressed Psoriasis Patients at Higher Risk of Psoriatic ArthritisInternet-Based CBT Effective for Depressive SymptomsCan Depression Up Odds for Arthritis Linked to Psoriasis?Postpartum Depressive Symptoms Fell in 2004 to 2012Hey Fellas, Depression Can Strike New Dads, TooDepression Often Untreated in Dialysis PatientsGDM Found to Increase Risk for Postpartum DepressionPostpartum Depression Affects New Dads, TooPanic Disorder May Up Odds of Depression Rx Side EffectsSometimes the Holidays Aren't Always JollyPilots Suffer Depression, Suicidal Thoughts at Fairly High RatesMore Than 1 in 10 Pilots Suffer From Depression, Survey FindsSelf-Care Tools Cut Depression in AMD, Diabetic RetinopathyClinical Antecedents of Adolescent-Onset MDD IdentifiedAge-Related Cataract Linked to Depressive SymptomsDepression, Suicide Ideation Prevalent in Medical Students2 Out of 3 Depressed Teens Gain Lasting Benefits From TherapyAntidepressants + Exercise Beneficial in Late-Life Depression
Questions and AnswersLinks
Related Topics

Anxiety Disorders
Bipolar Disorder
Suicide
Addictions: Alcohol and Substance Abuse
Pain Management

Addition of Aripiprazole Ups Major Depressive Disorder Remission


HealthDay News
Updated: Jul 12th 2017

new article illustration

WEDNESDAY, July 12, 2017 (HealthDay News) -- For patients with major depressive disorder (MDD), augmentation with aripiprazole is associated with an increased likelihood of remission, according to a study published in the July 11 issue of the Journal of the American Medical Association.

Somaia Mohamed, M.D., Ph.D., from the VA Connecticut Healthcare System in West Haven, and colleagues examined the relative effectiveness and safety of three treatments for MDD in patients unresponsive to at least one antidepressant course. Patients were randomly assigned to switch to a different antidepressant, bupropion (switch group, 511 patients); augment current treatment with bupropion (augment-bupropion group, 506 patients); or augment with an atypical antipsychotic, aripiprazole (augment-aripiprazole group, 505 patients) for 12 weeks and up to 36 weeks (acute treatment and continuous phases).

The researchers found that at 12 weeks, the remission rates were 22.3, 26.9, and 28.9 percent for the switch, augment-bupropion, and augment-aripiprazole groups; the augment-aripiprazole group exceeded the switch group in remission (relative risk, 1.3). The augment-aripiprazole group had greater response compared with the switch or augment-bupropion groups (74.3 versus 62.4 percent [relative risk, 1.19] and 65.6 percent [relative risk, 1.13], respectively). There were no significant treatment differences for relapse. The bupropion groups had more anxiety (24.3, 22.5, and 16.6 percent in the switch, augment-bupropion, and augment-aripiprazole groups, respectively).

"Given the small effect size and adverse effects associated with aripiprazole, further analysis including cost-effectiveness is needed to understand the net utility of this approach," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Bristol-Myers Squibb, which provided aripiprazole for use in the study.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)